Novel CAR-T therapy shows promise against hard-to-treat cancer –...

Patients with Hodgkin lymphoma and other CD30+ lymphomas refractory to treatment or relapse have very few therapeutic options today. Although in other haematological neoplasms, such as leukaemias or B-cell lymphomas, CAR-T cell therapies are showing very positive results, in this particular case they are demonstrating many limitations due to the lack of persistence of modified cells and the rapid relapse of patients.

In a phase I clinical trial, the results of which have been published in the prestigious journal Blood, it is revealed that this new CART30 promotes the expansion of memory T cells, which translates into durable responses and a better clinical evolution in treated patients. Hodgkin lymphoma and other CD30+ lymphomas have represented a challenge for the medical community, especially in refractory or relapse cases, where conventional treatments ha…

Novel CAR-T therapy shows promise against hard-to-treat cancer –...

Last Updated on April 29, 2025 by Team THIP New Delhi, April 29 (IANS) A team of Brazilian researchers has developed an innovative CAR-T cell therapy that showed positive results in patients with a refractory type of lymphoma — cancer in lymph nodes, spleen, and bone marrow. HSP-CAR30 is the first European CAR-T30 study to […] The post Novel CAR-T therapy shows promise against hard-to-treat cancer appeared first on THIP Media.

Breakthrough CAR-T Therapy Shows Promising Outcomes in Patients with

A groundbreaking advancement in the fight against refractory CD30-positive lymphomas has emerged from researchers at the Sant Pau Research Institute (IR Sant Pau), in conjunction with Sant Pau Hospital and the Josep Carreras Leukaemia Research Institute. They have developed an innovative chimeric antigen receptor T-cell (CAR-T) therapy known as HSP-CAR30, specifically engineered to target the CD30 protein, a marker expressed on Hodgkin lymphoma …